Clinical trial · Interventional
Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma
NCT02017353CI-TRIAL-00024429completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This therapy aims to determine whether curcumin can inhibit tumor induced inflammation in patients with endometrial carcinoma. In addition, curcumin could possibly induce a better functioning of chemotherapy and a decrease in toxicity from chemotherapy. Various studies have demonstrated that curcumin can have an effect on tumor growth and the development of metastases.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Carcinoma | Endometrial Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Curcuphyt | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Curcuphyt
- description
- Intake of Curcuphyt capsules, 2 g per day during 2 weeks
- interventionNames
- Dietary Supplement: Curcuphyt
Primary outcomes (1)
- measure
- Change in inflammatory markers in peripheral blood from baseline
- timeFrame
- baseline, day 1, day 7, day 14, day 21
Secondary outcomes (2)
- measure
- Number of Participants with Serious and Non-Serious Adverse Events
- timeFrame
- up to 3 weeks
- measure
- Change from Baseline in Quality of Life score
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Endometrial carcinoma at time of recurrence * No life-threatening metastases Exclusion Criteria: * Other active malignancy * Documented autoimmune disease * Currently ongoing immunosuppressive therapy * Simultaneous treatment according to other clinical trials * Documented immune deficiency
References
Publications (0)
Data not yet available
No reference posted for this study.